Please rate this video

iwCLL 2017 | Next-generation BTK inhibitors and their value in CLL

Please rate this video

Anthony Mato

Anthony Mato, MD, MSCE, from the Hospital of the University of Pennsylvania, Philadelphia, PA, talks to us about next-generation BTK inhibitors such as acalabrutinib and their results in clinical trials, but notes that long-term follow-up is still required to assess their effectiveness. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter